Cost-effectiveness of adrenaline for out-of-hospital cardiac arrest.

ABSTRACT:

Background

The 'Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration In Cardiac Arrest' (PARAMEDIC2) trial showed that adrenaline improves overall survival, but not neurological outcomes. We sought to determine the within-trial and lifetime health and social care costs and benefits associated with adrenaline, including secondary benefits from organ donation.

Methods

We estimated the costs, benefits (quality-adjusted life years (QALYs)) and incremental cost-effectiveness ratios (ICERs) associated with adrenaline during the 6-month trial follow-up. Model-based analyses explored how results altered when the time horizon was extended beyond 6 months and the scope extended to include recipients of donated organs.

Results

The

SUBMITTER: Achana F 

PROVIDER: S-EPMC7520962 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature